Daiichi Sankyo Company (4568-TO)

FiercePharma  Apr 11  Comment 
Daiichi Sankyo today released its road map for the $3.2 all-stock Ranbaxy deal with Sun Pharmaceutical and the mile markers it sees to completion. It also provides some idea for drugmakers with products facing Ranbaxy generics of how quickly its...
Japan Today  Apr 7  Comment 
Daiichi Sankyo Co Ltd said on Monday that Sun Pharmaceutical Industries Ltd will buy its Indian unit Ranbaxy Laboratories Ltd, creating the world's fifth-largest speciality generics company. Daiichi Sankyo said in a statement that it agrees to...
Financial Times  Feb 2  Comment 
Questions remain about why Daiichi Sankyo, the Japanese owner of the Indian drugmaker, is still struggling to improve quality after five years
Wall Street Journal  Jan 31  Comment 
Japanese drug maker Daiichi Sankyo says it will take further action to improve quality control at its Ranbaxy unit, following a U.S. ban on ingredients made at a plant in India.
Reuters  Jan 24  Comment 
Japan's Nikkei share average dropped to a one-month low on Friday morning as weak Chinese manufacturing activity data continued to hurt sentiment - keeping the market risk-averse before the U.S. Federal Reserve's policy-setting meeting next week.
FierceBiotech  Nov 20  Comment 
Daiichi Sankyo's atrial fibrillation-treating edoxaban posted promising results in Phase III, matching the stroke-prevention prowess of warfarin with a better safety profile, but the drug may struggle to carve out market share in a cluttered space.
FiercePharma  Nov 20  Comment 
The good news for Daiichi Sankyo: Its new anticoagulant drug matched the old standard-issue drug warfarin at preventing stroke and blood clots. And as far as safety goes, edoxaban beat warfarin by a significant stretch. That's an entree into the...
Wall Street Journal  Nov 19  Comment 
Daiichi Sankyo's blood thinner edoxaban proved at least as effective in a major trial as the widely used warfarin in reducing the risk of stroke among patients with an irregular heartbeat called atrial fibrillation
Forbes  Nov 19  Comment 
Edoxaban, a direct oral factor Xa inhibitor under development by Daiichi Sankyo, is the latest in the series of new oral anticoagulants seeking to take over the troubled role of warfarin in clinical practice. The results of ENGAGE-AF-TIMI...
FiercePharma  Nov 11  Comment 
After agreeing to pay $500 million to U.S. authorities in May, Japan's Daiichi Sankyo let it be known it was taking "available legal remedies" against certain shareholders that it says misrepresented critical information about the regulatory...

You may also be interested in articles related to Daiichi Sankyo Company (4568-TO):
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki